Current status of clinical research on novel treatment of diabetic nephropathy

doi:10.3877/cma.j.issn.2095-3216.2013.01.009

Abstract

Abstract:

Diabetic nephropathy (DN) is one of the serious complications of diabetes, and is the leading cause of end-stage renal disease in developed countries. In recent years, based on several largescale, randomized controlled trials, treatment of DN is facing new challenges. ＂Novel drugs＂ have been successively applied to the treatment of DN. Here, we have reviewed the new progress of DN treatment in recent years according to the evidence-based medicine combined with the therapeutic targets of DN.

Key words: Chronic kidney disease, Diabetic nephropathy, End-stage renal disease, Randomized controlled trials

Mo-yan LIU, Han-yu ZHU, Guang-yan CAI, Xiang-mei CHEN. Current status of clinical research on novel treatment of diabetic nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2013, 02(01): 42-47.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2013.01.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2013/V02/I01/42

References 55

1	王克安. 中国糖尿病的防治和研究 [J]. 中华流行病学杂志,1999, 20(5): 6-9.
2	Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362(12): 1090-1101.
3	Wild S, Roglic G, Green A, et al. Global prevalence of diabetes:estimates for the year 2000 and projections for 2030 [J]. Diabetes care, 2004, 27(5): 1047-1053.
4	Standards of medical care for patients with diabetes mellitus [J].Diabetes care, 2003, 26 Suppl 1: 33-50.
5	Ritz E, Zeng XX, Rychlik I. Clinical manifestation and natural history of diabetic nephropathy [J]. Contrib Nephrol, 2011, 170:19-27.
6	金波, 刘志红, 葛永纯, 等. 肾活检患者中糖尿病肾病流行病学特点的变迁 [J]. 肾脏病与透析肾移植杂志, 2009, 18(02):133-139.
7	Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats [J]. Kidney Int, 1992, 42(2): 285-291.
8	Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. N. A. S. randomized trial [J].J Am Soc Nephrol, 2002, 13(6): 1615-1625.
9	Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial [J]. Am J Kidney Dis, 2011, 58(5):729-736.
10	Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy[J]. J Am Soc Nephrol, 2012, 23(1): 123-130.
11	RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease [J]. J Am Soc Nephrol,2009, 20(8): 1765-1775.
12	Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy [J]. J Am Soc Nephrol, 2011, 22(6): 1144-1151.
13	Aggarwal HK, Jain D, Talapatra P, et al. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy [J]. Ren fail, 2010,32(8): 941-946.
14	Burney BO, Kalaitzidis RG, Bakris GL. Novel therapies of diabetic nephropathy [J]. Curr Opin Nephrol Hypertens, 2009,18(2): 107-111.
15	Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes [J]. Kidney Int, 2008, 73(12): 1419-1425.
16	Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy [J]. N Engl J Med,2008, 358(23): 2433-2446.
17	Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE):rationale and study design [J]. Nephrol Dial Transplant, 2009,24(5): 1663-1671.
18	Parving HH, Brenner BM, McMurray JJ, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) [J]. J Renin Angiotensin Aldosterone Syst, 2012,13(3): 387-393.
19	Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded;product information updated. http://www.reuters.com/article/2012/04/19/idUS234551+19-Apr-2012+HUG20120419.Accessed Apr 2012.
20	Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes [J]. Endocr rev, 2002, 23(5): 599-622.
21	Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes [J]. N Engl J Med,2011, 365(4): 327-336.
22	De Zeeuw D, Akizawa T, Agarwal R, et al. Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) [J]. Am J Nephrol, 2013, 37(3): 212-222.
23	Endo K, Miyashita Y, Sasaki H, et al. Probucol delays progression of diabetic nephropathy [J]. Diabetes Res Clin Pract, 2006, 71(2):156-163.
24	Chen YM, Ng YY, Lin SL, et al. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats [J]. Nephrol Dial Transplant,2004, 19(5): 1106-1115.
25	Lin SL, Chen YM, Chien CT, et al. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney [J]. J Am Soc Nephrol, 2002, 13(12): 2916-2929.
26	Roozbeh J, Banihashemi MA, Ghezlou M, et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy [J]. Renal fail, 2010, 32(2):172-178.
27	Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, et al.Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results [J]. J Diabetes Complications, 2011, 25(5): 314-319.
28	Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients study. Clinical Trial NCT01382302. www. clinicaltrials.gov. Accessed December, 2011.
29	Diaz VA, Mainous AG, Carek PJ, et al. The association of vitamin D deficiency and insufficiency with diabetic nephropathy:implications for health disparities [J]. J Am Board Fam Med,2009, 22(5): 521-527.
30	Porsti IH. Expanding targets of vitamin D receptor activation:downregulation of several RAS components in the kidney [J].Kidney Int, 2008, 74(11): 1371-1373.
31	Rojas-Rivera J, De La Piedra C, Ramos A, et al. The expanding spectrum of biological actions of vitamin D [J]. Nephrol Dial Transplant, 2010, 25(9): 2850-2865.
32	De Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial [J]. Lancet, 2010, 376(9752): 1543-1551.
33	Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensinaldosterone system inhibition [J]. Kidney Int, 2011, 80(8): 851-860.
34	Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis [J]. Am J Kidney Dis, 2010, 55(5): 835-847.
35	Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes [J]. J Clin Endocrinol Metab, 2010, 95(10): 4560-4565.
36	Nissen SE, Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality [J]. Arch Intern Med, 2010, 170(14): 1191-1201.
37	Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone [J]. Fundam Clin Pharmacol, 2009, 23(6): 675-679.
38	Komers R, Oyama TT, Beard DR, et al. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure [J]. Kidney Int, 2011, 79(4): 432-442.
39	Kolavennu V, Zeng L, Peng H, et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control [J]. Diabetes, 2008, 57(3): 714-723.
40	Komers R . Rho kinase inhibition in diabetic nephropathy [J].Curr Opin Nephrol Hypertens, 2011, 20(1): 77-83.
41	Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology [J]. Circ Res, 2006, 98(3): 322-334.
42	张慧, 朱孝春, 王莉, 等. 法舒地尔治疗2型糖尿病伴白蛋白尿的临床观察 [J]. 东南国防医药, 2011(01): 66-67.
43	Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy [J]. Am J Pathol, 2003,162(4): 1123-1137.
44	Reiniger N, Lau K, McCalla D, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse [J].Diabetes, 2010, 59(8): 2043-2054.
45	Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy [J]. Am J Nephrol, 2004, 24(1): 32-40.
46	Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy [J]. Am J Nephrol,2007, 27(6): 605-614.
47	Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy [J]. J Am Soc Nephrol, 2012, 23(1): 131-136.
48	House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial [J]. JAMA, 2010, 303(16): 1603-1609.
49	Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease [J]. Eur J Clin Invest, 2006,36( Suppl) 3: 78-88.
50	Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy [J]. J Am Soc Nephrol, 2010, 21(3): 527-535.
51	Brownlee M. Biochemistry and molecular cell biology of diabetic complications [J]. Nature, 2001, 414(6865): 813-820.
52	Meier M, Park JK, Overheu D, et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model[J]. Diabetes, 2007, 56(2): 346-354.
53	Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes [J]. Diabetes care, 2007, 30(4):995-996.
54	Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes [J]. Diabetes care, 2005,28(11): 2686-2690.
55	Ghorbani A, Omidvar B, Beladi-Mousavi SS, et al. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial [J]. Nefrologia, 2012, 32(6):790-796.

[1]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[2]	Branch of Organ Transplantation of Chinese Medical Association, Branch of Kidney Transplantation, China International Exchange and Promotive Association for Medical and Health Care. Clinical guideline for diagnosis and treatment of combined pancreas and kidney transplantation in China [J]. Chinese Journal of Transplantation(Electronic Edition), 2024, 18(03): 129-147.
[3]	Shuxun Ling, Yue Tu, Siyi Liu. Visualization analysis on knowledge map of mesenchymal stem cells in the research field of chronic kidney disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 73-82.
[4]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Clinical practice guidelines for kidney injury management of liver transplant recipients in China(2023 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 276-288.
[5]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[6]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[7]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[8]	Jun Liu, Kehong Chen. Research progress on the effect of exercise intervention in patients with end-stage renal disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(04): 219-225.
[9]	Xiaolong Wang, Jie Wu, Shuwei Duan, Chaohui Wang, Na Pan, Yuanyuan Bai, Hangtian Li, Guangyan Cai. Effect of different levels of physical activity on the prognosis of patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 121-128.
[10]	Wuhao Xiao, Kanghan Liu. Research progress on the treatment of osteoporosis in patients with advanced chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 92-96.
[11]	Jinyi Zhang, Yuehong Li. Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 97-100.
[12]	Yansheng Wu, Xianwen Zhang, Lin Wang. Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 101-105.
[13]	Ling Qiu, Xuli Zhu, Jian Pu, Miaomiao Xing, Jialing Wu. Correlation between ecological characteristics of intestinal flora and gastrointestinal dysfunction in patients with diabetic nephropathy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 453-458.
[14]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.
[15]	Gaoting Ma, Yingting Zuo, Shaoyuan Lei, Ran Mo, Yifan Wu, Shujuan Meng, Ziying Jiang, Yue Wu, Yi Ren, Pingping Wang, Qian Zhang, Qingfeng Ma, Haiqing Song, Lianmei Zhong, Junwei Hao. Current applications and future prospects of target trial emulation in the field of cerebrovascular diseases [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(03): 277-280.

Please choose a citation manager

Content to export